Clioquinol / Hydrocortisone Topical Dosage

Usual Adult Dose for Dermatitis

Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed

Comments: This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.

Uses: Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:

• Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo

Usual Adult Dose for Eczema

Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed

Comments: This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.

Uses: Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:

• Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo

Usual Adult Dose for Pruritus

Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed

Comments: This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.

Uses: Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows:

• Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo

Usual Pediatric Dose for Dermatitis

2 years or older: Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed

Comments:

• This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.
• Administration of topical corticosteroids to children should be limited to the lowest effective dose for the shortest duration possible.
• Chronic corticosteroid therapy may interfere with growth and development in pediatric patients.

• Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo

Usual Pediatric Dose for Eczema

2 years or older: Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed

Comments:

• This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.
• Administration of topical corticosteroids to children should be limited to the lowest effective dose for the shortest duration possible.
• Chronic corticosteroid therapy may interfere with growth and development in pediatric patients.

• Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo

Usual Pediatric Dose for Pruritus

2 years or older: Apply a thin layer topically to the affected area(s) 2 to 4 times a day or as directed

Comments:

• This product has not been found by the US FDA to be safe and effective and the product labeling has not been approved.
• Administration of topical corticosteroids to children should be limited to the lowest effective dose for the shortest duration possible.
• Chronic corticosteroid therapy may interfere with growth and development in pediatric patients.

• Possibly effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Data not available

Precautions

Safety and efficacy have not been established in patients younger than 2 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:

• For external use only.
• Avoid use in or around the eyes.

• Protect from freezing.

• May produce false-positive ferric chloride test results for phenylketonuria (PKU) if iodochlorhydroxyquin is present in the neonate's diaper or urine.
• Pediatric therapy continuing for longer than 2 weeks and consisting of doses in excess of 2 applications per day (with low-potency corticosteroids) should be carefully evaluated by the physician; especially important if the medication is applied to more than 5% to 10% of the body surface or if an occlusive dressing is used.
• A tight-fitting diaper or one covered with plastic pants may constitute an occlusive dressing.

• Endocrine: Urinary free cortisol and adrenocorticotropic hormone (ACTH) stimulation tests may be helpful in evaluating hypothalamic-pituitary-adrenal (HPA) axis suppression.

• Report any signs of local adverse reactions especially under occlusive dressing.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer